Showing 341-360 of 753 for: Cochrane Systematic Reviews > Pharmacotherapeutics 
- HMG CoA reductase inhibitors (statins) for dialysis patients
Cochrane Systematic Reviews, 2-Sep-2013
People with advanced kidney disease treated with dialysis experience mortality rates from cardiovascular disease that are substantially higher than for the general population. Studies that have assessed the benefits of statins (HMG CoA reductase inhibitor
- Holding chambers versus nebulisers for inhaled steroids in chronic asthma
Cochrane Systematic Reviews, 26-Apr-2009
Inhaled corticosteroids are available in the form of a suspension for nebulisation, although the role of this mode of therapy in the treatment of chronic asthma is still unclear.
- Home versus in-patient treatment for deep vein thrombosis
Cochrane Systematic Reviews, 13-Feb-2011
Deep vein thrombosis (DVT) occurs when a blood clot blocks blood flow through a vein. This can happen after surgery, trauma, or when a person has been immobile. Clots can dislodge and block blood flow to the lungs, causing death. Heparin is a blood-thinni
- Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients
Cochrane Systematic Reviews, 2-Nov-2012
Sepsis is a common and frequently fatal condition. Human recombinant activated protein C (APC) has been introduced to reduce the high risk of death associated with severe sepsis or septic shock. This systematic review is an update of a Cochrane review ori
- Ibuprofen for Alzheimer's disease
Cochrane Systematic Reviews, 13-May-2008
Non-steroidal antiinflammatory drugs such as ibuprofen may have a role in the treatment of conditions characterized by inflammatory processes. Ibuprofen may attenuate the effects of modulators of inflammation that have been implicated in the pathogenesis
- Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy
Cochrane Systematic Reviews, 26-Nov-2014
Epilepsy is defined as the tendency to spontaneous, excessive neuronal discharge manifesting as seizures. It is a common disorder with an incidence of 50 per 100,000 per year and a prevalence of 0.5% to 1% in the developed world (Hauser 1993).
- Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates
Cochrane Systematic Reviews, 11-Nov-2008
Exchange transfusion and phototherapy have traditionally been used to treat jaundice and avoid the associated neurological complications. Exchange transfusion is not without risk and intravenous immunoglobulin has been suggested as an alternative therapy
- Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients
Cochrane Systematic Reviews, 17-Mar-2010
Cytomegalovirus (CMV) is the most common virus causing disease and death in solid organ transplant recipients during the first six months post-transplant. Previous systematic reviews have demonstrated the efficacy of antiviral medications used prophylacti
- Immunosuppressive agents for myasthenia gravis
Cochrane Systematic Reviews, 2-Nov-2008
The benefits of different immunosuppressants for myasthenia gravis (MG) are unclear.
- Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis
Cochrane Systematic Reviews, 27-Jul-2008
Immunosuppressive and cytotoxic agents have been used as both an alternative to oral corticosteroids, and as a means of maintaining a low dose of steroids in the treatment of pulmonary sarcoidosis.
- Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies
Cochrane Systematic Reviews, 17-Apr-2012
Serum monoclonal anti-myelin-associated glycoprotein antibodies may be pathogenic in some people with immunoglobulin M (IgM) paraprotein and demyelinating neuropathy. Immunotherapies aimed at reducing the level of these antibodies might be expected to be
- Infusion techniques for peripheral arterial thrombolysis
Cochrane Systematic Reviews, 17-Nov-2021
Acute limb ischaemia usually is caused by a blood clot blocking an artery or a bypass graft. Severe acute ischaemia will lead to irreversible damage to muscles and nerves if blood flow is not restored in a few hours. Once irreversible damage occurs, amput
- Inhaled beta2-agonists for asthma in mechanically ventilated patients
Cochrane Systematic Reviews, 25-Oct-2011
A small number of patients with acute severe asthma require intubation and positive pressure ventilation. The beneficial effects of inhaled bronchodilators on acute asthma in spontaneously breathing subjects are well established, but there remain importan
- Inhaled beta2-agonists for non-specific chronic cough in children
Cochrane Systematic Reviews, 29-Mar-2009
The pathophysiology of so called 'cough variant asthma' has not received a great deal of research interest and opinion lies divided as to whether it is really asthma or not. The proponents of cough variant asthma suggest a therapeutic trial of medications
- Inhaled bronchodilators for cystic fibrosis
Cochrane Systematic Reviews, 11-Feb-2016
Recurrent wheeze and breathlessness are common in people with cystic fibrosis, and bronchodilators are commonly prescribed. Despite their wide-scale and often long-term use, there is limited objective evidence about their efficacy in cystic fibrosis (CF).
- Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease
Cochrane Systematic Reviews, 29-Jul-2008
Inhaled corticosteroids form the main therapy for asthma, but there is increasing concern about the potential systematic effects of long-term inhaled corticosteroids including their effect on bone metabolism and bone loss.
- Inhaled corticosteroids compared to placebo for prevention of exercise induced bronchoconstriction
Cochrane Systematic Reviews, 20-Jan-2009
The pathogenesis of exercise induced bronchoconstriction is likely multifactorial and is not completely understood. Inflammation plays an important role in the pathogenesis of exercise induced bronchoconstriction in asthmatic subjects but the evidence see
- Inhaled corticosteroids for cystic fibrosis
Cochrane Systematic Reviews, 8-Oct-2014
Reduction of lung inflammation is one of the goals of cystic fibrosis therapy. Inhaled corticosteroids are often used to treat children and adults with cystic fibrosis. The rationale for this is their potential to reduce lung damage arising from inflammat
- Inhaled corticosteroids for non-specific chronic cough in children
Cochrane Systematic Reviews, 29-Mar-2009
Cough in isolation of other clinical features is known as non-specific cough, which has been defined as non-productive cough in the absence of identifiable respiratory disease or any known aetiology. In children with non-specific cough the possibility of
- Inhaled corticosteroids for stable chronic obstructive pulmonary disease
Cochrane Systematic Reviews, 1-Jun-2012
The role of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) has been the subject of much controversy. Major international guidelines recommend selective use of ICS. Recently published meta-analyses have reported conflicting f
